Supporting 0 to 1 (Idea to NewCo)
Biotech Startups
Viva Ventures Biotech Fund
We are a VC fund focuses on investments in global first-in-class, discovery-stage biotech startups with significant growth potential, and helps them from 0 to 1 , idea to NewCo. Viva Ventures is one of very few biotech VCs that have extensive expertise and industry know-how for early stage investments.
Supporting Biotech Startups since 2008
Viva Ventures Biotech Fund is backed by the founders of top biotech startups and chief scientists of incubator centers, giving us access to the top startups around the world including Viva Biotech incubators, Boston CIC, and Hong Kong Science Park.
Co-investment Partners
On August 26，2021，the Hong Kong Innovation and Technology Commission announced that the Innovation and Technology Venture Fund (ITVF) has added Viva Ventures Biotech, LP. as one of the co-investment partners (CPs).
Click to read: Innovation and Technology Venture Fund adds two co-investment partners
Portfolio Companiest
Our Strategies
Our Investment Thesis:
Early Stage = Achieve Superior Return
How to Achieve Higher Success Rate:
Genetic Linkage, Biomarkers and SBDD
Phase 2a/2 Clinical Success Rates
Impact of Structure-Based Drug Design (SBDD)
*Source: Nature Review, Volume 13, June 2014
-
Projects that showed greater confidence in target validation through human genetic target linkage to the disease were less likely to fail owing to a lack of efficacy
-
73% of projects with some genetic linkage of the target to the disease were active or successful in Phase II compared with 43% of projects without such data, also that of projects with biomarkers could exceed 80%
Deal Flow Funnel：To Select Top 2% Deals
Global Ecosystem for Deal Sourcing and Exiting
Global Pharmas and Biotech Companies Include:
Our Portfolio Overview
Diversified Portfolio
* Including all the projects invested by Fund I, Fund II and Fund III
Our Team
Fund Management
Jun Mao, PhD (UK)
Honorable President of The University of Hong Kong Foundation
Founder and Chairwoman
-
Founding Director of Viva Biotech, a HK listed company with 100X+ investment return
-
Active biotech investor since 2008, invested 21 biotech and drug discovery startups
-
Working at top tier IB in City of London 1996-2009 after Ph.D in Theoretical Physics (UK)
-
Founder of JMCR family office*
*JMCR family office was established in 2013, founded to manage the private assets for founder‘s family and close relations. Under the family office , JMCR Capital隽华资本 ® for investment fund and JMCR Partners隽华国际 ® for assets management, specialize in the fields of Private Equity and Quantitative Investment Strategy.
Raymond Lemin Wang
Managing Director
Celine Li Han
Managing Director
Andrew Chen
Managing Director
Lianfeng Lin, PhD
Research and Business
Development Scientist
Renfei Wang, PhD
Vice President
Ying Su
Operation Director
Wenjia Zhou
Finance Control
Carrie Lu
Investment Analyst
Winners Select Winners ：Peer review platform formed by winning Venture Partners, EIR, Advisory Partners, Founders
Who are they
-
with 20+ years top biotech VC and/or drug discovery businesses experience
-
Well-known first-in-class drug inventor with successful track record
-
Senior medical R&D management expert in clinical stage
-
Famous founder of drug commercialization in the US market
-
Founder of first-in-class drug startups and pharmaceutical fund in China
Their track record
Contact Us
Send us a business plan
If you have a great early-stage biotechnological or pharmaceutical project align with our investment strategy, please send your business plan to info@vivaventuresbiotech.com. We look forward to it!